Kinghorn G R, Jeavons M, Rowland M, Abeywickreme I, Barton I G, Potter C W, Hickmott E A
Genitourin Med. 1985 Dec;61(6):387-90. doi: 10.1136/sti.61.6.387.
Forty patients were entered into a randomised placebo controlled crossover study to assess the efficacy and safety of oral acyclovir 200 mg four times a day in the prophylaxis of recurrent genital herpes. Each treatment began during a recurrence and continued for a maximum of 84 days or until the onset of the next recurrence, when the alternate medication was started. Of 28 patients who completed both treatment courses, only three developed a recurrence while taking acyclovir compared with 26 while taking placebo. The mean time to first recurrence was more than 84 days in patients receiving acyclovir and 24 days in patients receiving placebo (p less than 0.001). The mean time to first recurrence after treatment with acyclovir ceased was 16 days. Adverse events, though thought unlikely to be related to treatment, necessitated the withdrawal from the study of two patients while taking acyclovir and one patient while taking placebo. No clinically important effects on haematological or biochemical variables occurred during the acyclovir treatment. All viral isolates tested after treatment remained sensitive to acyclovir. Acyclovir prophylaxis of recurrent genital herpes is effective and safe but does not appear to influence the natural history of the disease after cessation of 84 days' continuous treatment.
40名患者参与了一项随机安慰剂对照交叉研究，以评估每日4次口服200毫克阿昔洛韦预防复发性生殖器疱疹的疗效和安全性。每次治疗均在复发期间开始，持续最长84天或直至下次复发开始，此时开始使用另一种药物。在完成两个疗程治疗的28名患者中，服用阿昔洛韦时只有3人复发，而服用安慰剂时为26人。接受阿昔洛韦治疗的患者首次复发的平均时间超过84天，接受安慰剂治疗的患者为24天（p<0.001）。停止阿昔洛韦治疗后首次复发的平均时间为16天。不良事件虽被认为不太可能与治疗相关，但导致2名服用阿昔洛韦的患者和1名服用安慰剂的患者退出研究。在阿昔洛韦治疗期间，血液学或生化指标未出现具有临床意义的变化。治疗后检测的所有病毒分离株对阿昔洛韦仍敏感。连续84天治疗后停止使用阿昔洛韦，阿昔洛韦预防复发性生殖器疱疹有效且安全，但似乎不影响疾病的自然病程。
